Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

United Therapeutics Corporation

https://www.unither.com/

Latest From United Therapeutics Corporation

Busy 2021 Ahead For Almirall On Business And Clinical Fronts

Gianfranco Nazzi will be taking over as head of the Spanish company shortly and the Barcelona-based firm's prospects look good as its dermatology portfolio and pipeline blossom.

Dermatology Deals

CFO Joshua Smiley On Lilly’s Next Decade Of Growth

Lilly is planning for growth even beyond the loss of patent protection for Trulicity in 2027. In addition to internal R&D, Smiley said a third of new drugs will come from business development. 

Growth Strategy

Arena Updates Etrasimod Timelines, Introduces New Drug Candidate

CEO Amit Munshi told the J.P. Morgan meeting the company will double the size of its clinical-stage cardiovascular disease pipeline with the addition of temanogrel.

Companies Cardiovascular

Academia Meets The Market – Part One

New drug development is an increasingly communal enterprise. In Vivo examines how one major US academic institution – the University of California at Los Angeles (UCLA) – is expanding its range of research contacts to open new areas of therapy and shorten the transition from bench to the bedside.  Its commercial impact is considerable: over the past two decades, private-sector VC’s have invested more than $2bn in UCLA-backed innovations, with 26 start-ups launched through the university in 2019 alone. Amir Naiberg, UCLA’s point man on technology transfer, explains the factors that have made the university a successful advocate for partnerships that produce results for patients.

Business Strategies C-Suite Speaks
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Lung Biotechnology PBC
    • Lung Rx, Inc.
    • SteadyMed Ltd.
    • SteadyMed Therapeutics, Inc.
    • Unither Pharmaceuticals
    • Unither Virology
UsernamePublicRestriction

Register